CRISPR Therapeutics (CRSP) Income Statement: Revenue & Earnings

CRISPR Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

CRISPR Therapeutics AG income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	37.31	371.21	1.20	913.08	0.72	289.59	3.12
Cost of Revenue	430.90	130.25	571.90	101.18	269.41	0.00	0.00
Gross Profit	-393.59	371.21	-570.70	811.90	0.72	289.59	0.00
Operating Expenses
Research & Development	320.65	387.33	461.65	340.57	266.95	179.36	113.77
Selling, General & Administrative	72.98	76.16	102.46	99.69	88.21	63.49	48.29
Operating Expenses	72.98	593.74	102.46	438.38	355.15	242.85	162.07
Operating Income	-466.57	-222.54	-673.16	373.53	-354.44	46.74	-158.94
Other Income/Expense
Interest Income	103.90	71.82	22.66	6.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	103.90	-71.82	22.66	6.00	-6.38	-20.57	-5.49
Income
Income Before Tax	-362.67	-150.72	-650.50	379.53	-348.06	67.31	-164.43
Income Tax Expense	3.59	2.89	-0.33	1.87	0.81	0.45	0.55
Net Income	-366.25	-153.61	-650.18	377.66	-348.87	66.86	-164.98
Net Income - Continuous Operations	-366.25	-153.61	-650.18	377.66	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-447.31	-130.89	-648.99	391.48	-345.25	72.03	-155.42
EBIT	-466.57	-150.72	-673.16	373.53	-354.44	67.31	-158.94
Depreciation & Amortization	19.26	19.80	24.17	17.95	9.10	4.70	0.00
Earnings Per Share
Basic EPS	-4.00	-2.00	-8.00	5.00	-5.00	1.00	-3.00
Diluted EPS	-4.00	-2.00	-8.00	5.00	-5.00	1.00	-3.00
Basic Shares Outstanding	84.36	79.22	77.75	75.95	65.95	54.39	47.96
Diluted Shares Outstanding	84.36	79.22	77.75	80.39	65.95	56.93	47.96